|
ERC1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.19870000037103E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.44860000018366E-07 |
| Normal-vs-Stage2 |
3.094400E-02 |
| Normal-vs-Stage3 |
1.23799999995899E-06 |
| Normal-vs-Stage4 |
9.01400000197228E-08 |
| Stage1-vs-Stage2 |
9.188100E-02 |
| Stage1-vs-Stage3 |
4.585400E-01 |
| Stage1-vs-Stage4 |
3.323900E-02 |
| Stage2-vs-Stage3 |
4.573900E-02 |
| Stage2-vs-Stage4 |
5.940300E-03 |
| Stage3-vs-Stage4 |
2.096800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.60619999709655E-08 |
| Normal-vs-AfricanAmerican |
1.528960E-01 |
| Normal-vs-Asian |
6.41499999999295E-05 |
| Caucasian-vs-AfricanAmerican |
3.348000E-02 |
| Caucasian-vs-Asian |
8.789400E-01 |
| AfricanAmerican-vs-Asian |
3.800200E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.48529999999258E-06 |
| Normal-vs-Female |
3.7409999997795E-07 |
| Male-vs-Female |
4.445200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.22619999999951E-05 |
| Normal-vs-Age(41-60Yrs) |
1.62349999999201E-06 |
| Normal-vs-Age(61-80Yrs) |
1.46609999995828E-06 |
| Normal-vs-Age(81-100Yrs) |
4.680400E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.098200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.747000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.798000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.799800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.528400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.618000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.568120E-02 |
| Classical-VS-Follicular |
6.241600E-01 |
| Classical-VS-Other |
1.408970E-01 |
| Classical-VS-Normal |
4.23760000001216E-06 |
| Tall-VS-Follicular |
8.260200E-02 |
| Tall-VS-Other |
5.914800E-01 |
| Tall-VS-Normal |
6.59080000020573E-07 |
| Follicular-VS-Other |
2.214400E-01 |
| Follicular-VS-Normal |
9.60669999999775E-05 |
| Other-VS-Normal |
3.904100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.71163999999058E-05 |
| Normal-vs-N1 |
3.58330000116425E-08 |
| N0-vs-N1 |
9.402000E-03 |
|
|
